Spruce Biosciences (SPRBD) & The Competition Head-To-Head Survey

Institutional & Insider Ownership

91.7% of Spruce Biosciences shares are owned by institutional investors. Comparatively, 24.8% of shares of all “Biotechnology” companies are owned by institutional investors. 6.9% of Spruce Biosciences shares are owned by insiders. Comparatively, 20.8% of shares of all “Biotechnology” companies are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Profitability

This table compares Spruce Biosciences and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Spruce Biosciences	N/A	N/A	N/A
Spruce Biosciences Competitors	-15,247.28%	32.46%	-33.43%

Risk & Volatility

Spruce Biosciences has a beta of 2.43, suggesting that its stock price is 143% more volatile than the S&P 500. Comparatively, Spruce Biosciences’ rivals have a beta of 1.38, suggesting that their average stock price is 38% more volatile than the S&P 500.

Valuation & Earnings

This table compares Spruce Biosciences and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Spruce Biosciences	N/A	N/A	-0.08
Spruce Biosciences Competitors	$163.23 million	-$11.65 million	-427.17

Spruce Biosciences’ rivals have higher revenue, but lower earnings than Spruce Biosciences. Spruce Biosciences is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Summary

Spruce Biosciences beats its rivals on 5 of the 8 factors compared.